Myelodysplastic Syndromes (MDS) Clinical Trial
Official title:
A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndrome / Acute Myeloid Leukaemia, With Eltrombopag Support for Thrombocytopenia.
Myelodysplastic Syndrome (MDS) is a disease of the bone marrow characterized by
anemia,neutropenia, and thrombocytopenia (low red blood cell, white blood cell, and platelet
counts). MDS patients with thrombocytopenia who fail standard therapies require regular
platelet transfusions which are expensive and inconvenient, and are a risk for further
serious bleeding complications. The new treatment of MDS using azacitidine has shown to
increase the survival rate of MDS patients including to improve platelet production over
time. However,in the early cycles of treatment with azacitidine,the low platelet counts tend
to exacerbate before they provide any clinical benefit.
Eltrombopag is a drug designed to activate the thrombopoietin receptor. Eltrombopag has been
able to increase platelet counts in healthy Thrombocytopenia Purpura (ITP), a disease where
patients destroy their own platelets very rapidly and thus develop thrombocytopenia.
Eltrombopag is administered orally and is Therapeutic Goods Administration (TGA) approved
for the treatment of thrombocytopenia in patients with chronic ITP who failed to respond to
standard treatment.
This study is a single arm pilot study to evaluate the safety and tolerability of
Eltrombopag in the treatment of low platelet counts in adult subjects with MDS treated using
azacitidine This study also incorporates a correlative laboratory component designed to
determined the mechanism of action of 5-azacitidine +/- Eltrombopag and to determine a
baseline profile which may predict those most responsive. These studies will incorporate
gene methylation and expression, and immunoprofiling.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02550535 -
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00186342 -
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
|
N/A | |
Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
Completed |
NCT01355913 -
Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
|
||
Withdrawn |
NCT04985656 -
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
|
Phase 2 | |
Completed |
NCT01736683 -
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
|
Phase 2 | |
Completed |
NCT02333058 -
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
|
Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Withdrawn |
NCT04395092 -
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
|
Phase 2 | |
Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
Recruiting |
NCT05092451 -
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
|
Phase 1/Phase 2 | |
Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
Completed |
NCT02390414 -
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
|
||
Completed |
NCT01326377 -
ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT02966782 -
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
|
Phase 1 | |
Recruiting |
NCT02779569 -
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
|
N/A | |
Recruiting |
NCT02099669 -
Red Blood Cell Transfusion Thresholds and QOL in MDS
|
N/A | |
Completed |
NCT01392989 -
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
|
Phase 2 | |
Not yet recruiting |
NCT06398457 -
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
|
Early Phase 1 | |
Recruiting |
NCT02775383 -
The National Myelodysplastic Syndromes (MDS) Study
|